Five Years of Sacubitril/Valsartan—a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance

被引：0
|
作者：
Yee Soo Kim
Simerjeet Brar
Natalie D’Albo
Amit Dey
Sachin Shah
Sarju Ganatra
Sourbha S. Dani
机构：
[1] Lahey Hospital and Medical Center,Department of Internal Medicine
[2] Georgetown University Medical Center,Department of Internal Medicine
[3] Lahey Hospital and Medical Center,Beth Israel Lahey Health, Department of Cardiovascular Medicine
来源：
Cardiovascular Drugs and Therapy | 2022年 / 36卷
关键词：
Sacubitril/valsartan; FDA Adverse Event Reporting System; Real-world pharmacovigilance; Disproportionality analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：915 / 924
页数：9
相关论文
共 50 条
  • [1] Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance
    Kim, Yee Soo
    Brar, Simerjeet
    D'Albo, Natalie
    Dey, Amit
    Shah, Sachin
    Ganatra, Sarju
    Dani, Sourbha S.
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (05) : 915 - 924
  • [2] FIVE-YEAR SAFETY ANALYSIS OF SACUBITRIL/VALSARTAN: A COMPARATIVE ANALYSIS OF ADVERSE EVENTS IN RANDOMIZED CLINICAL TRIALS AND REAL-WORLD PHARMACOVIGILANCE
    Kim, Yee Soo
    Brar, Simerjeet
    D'Albo, Natalie
    Shah, Sachin
    Ganatra, Sarju
    Dani, Sourbha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 663 - 663
  • [3] Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials
    Wang, Li
    Fei, Yibo
    Qu, Han
    Zhang, Haiyang
    Wang, Yuanyuan
    Wu, Zhenghua
    Fan, Guorong
    JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2024, 10 (01)
  • [4] Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials
    Li Wang
    Yibo Fei
    Han Qu
    Haiyang Zhang
    Yuanyuan Wang
    Zhenghua Wu
    Guorong Fan
    Journal of Pharmaceutical Health Care and Sciences, 10
  • [5] Sacubitril/Valsartan: From Clinical Trials to Real-world Experience
    Joly J.M.
    Desai A.S.
    Current Treatment Options in Cardiovascular Medicine, 2018, 20 (6)
  • [6] Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials
    Qu, Han
    Wu, Jiaqi
    Ma, Cui
    Qiaolongbatu, Xijier
    Song, Xianmin
    Feng, Tingting
    Wu, Zhenghua
    Lou, Yuefen
    Fan, Guorong
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (01) : 201 - 210
  • [7] Updated insights on dementia-related risk of sacubitril/valsartan: A real-world pharmacovigilance analysis
    Chen, Congqin
    Ding, Lingqing
    Fu, Fang
    Xiao, Jie
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (09) : 2548 - 2554
  • [8] Safety and effectiveness of Sacubitril-Valsartan in a real-world population
    Mariana Tinoco, M.
    Cardoso, F.
    Dias, G.
    Pereira, T.
    Faria, B.
    Almeida, F.
    Leite, S.
    Lourenco, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 111 - 112
  • [9] The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data
    Lerman, Tsahi T.
    Greenberg, Noam
    Fishman, Boris
    Goldman, Adam
    Talmor-Barkan, Yeela
    Bauer, Menachem
    Goldberg, Idan
    Goldberg, Elad
    Kornowski, Ran
    Krause, Ilan
    Levi, Amos
    Cohen, Eytan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 397
  • [10] Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia
    Badreldin, Hisham A.
    Korayem, Ghazwa B.
    Alenazy, Basel A.
    Aljohani, Mousa H.
    Alshaya, Omar A.
    Al Sulaiman, Khalid
    Alabdelmuhsin, Lolwa
    Alenazi, Huda
    Almutairi, Dahlia M.
    Alanazi, Faisal
    Alobathani, Seba K.
    Alqannam, Ghada M.
    Almadani, Ohoud
    Aljuhani, Ohoud
    Hafiz, Awatif
    Aljowaie, Ghalyah
    Basha, Ehssan
    Alqahtani, Tariq
    Alhussein, Mosaad
    MEDICINE, 2023, 102 (51) : E36699
12345